US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial
ReutersAug 20, 2025 11:06 AM
Aug 20 (Reuters) - Rocket Pharmaceuticals RCKT.O said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Oracle Q1 FY2026 Earnings: Can Cloud and AI Drive the Next Stock Rally?
TradingKey - Oracle Corporation (NYSE: ORCL) will report Q1 FY2026 results after the close on Tuesday, September 9, 2025, with the webcasted conference call scheduled for 4:00 PM CT / 5:00 PM ET, making the print a fresh read-through on enterprise cloudTradingKey
12 hours ago
[U.S. IPO] Lambda, Rival to CoreWeave, Prepares for IPO Following $1.5 Billion Nvidia Order
TradingKey - Lambda, a small AI cloud service provider, is reportedly gearing up for an initial public offering (IPO) and has enlisted investment banks such as Morgan Stanley, JPMorgan Chase, and Citibank for assistance. The IPO could launch as early as the first half of 2026.TradingKey
13 hours ago
U.S. August Nonfarm Payroll Preview: Risks Focus on Downward Revision of July Data
TradingKey - On 5 September 2025, the U.S. Department of Labour will release the August Non-Farm Payrolls report. The market widely expects August to see an addition of 75,000 non-farm jobs, roughly in line with July’s 73,000.TradingKey
Thu, Sep 4
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
US NFP Nightmares Preview: A Tiny August Revision, a Huge Annual Benchmark Cut And a Fed in Flux
TradingKey - Wall Street expects modest job growth and a rebound in the unemployment rate in August NFP report, a balanced outcome that could support a September rate cut. However, a massive downward revision — a “terrifying scene” — and anomalies on the supply side could plunge the Fed into deeperTradingKey
Wed, Sep 3
 (1).jpg)
Tradingkey
